---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-010748"
form_type: "8-K"
ticker: "CTOR"
cik: "0001851484"
company_name: "CITIUS ONCOLOGY, INC."
filed_at: "2025-02-06T23:59:59+00:00"
generated_at: "2026-05-27T01:50:23.914688+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# LYMPHIR assigned permanent J-code J9161 by CMS, effective April 1, 2025

## Summary
- LYMPHIR (denileukin diftitox-cxdl) received permanent HCPCS J-code J9161 for IV use, 1 microgram.
- J-code effective April 1, 2025, for claims submission by healthcare providers.
- Code facilitates billing and reimbursement for commercial and government insurance (VA, DoD, Medicare).
- Chairman Leonard Mazur states milestone supports patient access and coding clarity.

## SEC filing metadata
- accession: 0001213900-25-010748
- form_type: 8-K
- ticker: CTOR
- cik: 0001851484
- company_name: CITIUS ONCOLOGY, INC.
- filed_at: 2025-02-06T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1851484/000121390025010748/0001213900-25-010748-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1851484/000121390025010748/ea0230157-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-010748
- JSON: https://secwatch.observer/filing/0001213900-25-010748.json
- Plain text: https://secwatch.observer/filing/0001213900-25-010748.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.